Blood plasma derivatives market seen reaching $86.68 billion by 2030

The global blood plasma derivatives market is projected to grow from $55.76 billion in 2025 to $86.68 billion by 2030, driven by rising hemophilia cases, immunodeficiency demand and expanded plasma collection networks. North America led the market in 2025, while Asia-Pacific is expected to post faster growth as healthcare spending and donation systems expand.

Why it matters: - Blood plasma derivatives treat bleeding disorders and immune deficiencies by replacing missing or deficient proteins in patients. - The market’s projected climb to $86.68 billion by 2030 signals sustained demand for therapies tied to rare and chronic conditions. - Faster plasma collection, purification and cold chain systems could improve access to these medicines across more regions.

What happened: - The Business Research Company released its Blood Plasma Derivatives Global Market Report 2026 on Nov. 6, 2026. - The report estimates the market will rise from $55.76 billion in 2025 to $60.76 billion in 2026. - The report projects a 9.0% CAGR in 2026 and a 9.3% CAGR from 2026 to 2030. - The market is forecast to reach $86.68 billion by 2030. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to grow faster than other regions.

The details: - Blood plasma derivatives are purified plasma proteins, including clotting factors and albumins. - These products are used to replace missing proteins in patients and support blood clotting and immune function. - Growth in recent years has been tied to better diagnosis of rare blood disorders, broader plasma collection efforts, higher demand for albumin therapies and advances in plasma fractionation. - Future growth is expected to come from more cases of immunodeficiency diseases, higher investment in plasma-derived treatments, wider plasma donation networks, pressure to build self-sufficiency in plasma supply and improvements in recombinant proteins. - Hemophilia is a major demand driver because plasma-derived medicines help manage hereditary and acquired clotting problems. - Factor VIII is used for hemophilia A, factor VIII/von Willebrand factor for von Willebrand disease and factor IX concentrates for hemophilia B. - The World Federation of Hemophilia’s 2024 Annual Global Survey reported a 6% increase in diagnosed hemophilia cases worldwide, along with similar increases in von Willebrand disease and other inherited bleeding disorders. - The report also cites growing awareness of immunodeficiency diseases, improved fractionation and purification, pathogen reduction methods and more efficient cold chain logistics. - The report says North America’s lead reflects established healthcare infrastructure and high plasma donation rates. - The report includes coverage of Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests the market is shifting from a niche therapeutic category to a broader global supply chain story. - The biggest growth levers are not just disease prevalence, but also manufacturing capacity, plasma collection infrastructure and distribution systems. - Asia-Pacific’s expected acceleration points to demand growth in markets that are still building donation networks and healthcare access.

What's next: - The report says deeper market intelligence in its 2026 edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics. - The Business Research Company is offering a free sample report and the full market report through its website.